PimasertibHydrochloride

Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).|Dapansutrile is an orally bioavailable inhibitor of the innate immune signaling sensor nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD containing protein 3; NALP3), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, dapansutrile specifically binds to and inhibits NLRP3, the sensor component of the NLRP3 inflammasome, and prevents the formation of the NLRP3 inflammasome. This inhibits the production of the pro-inflammatory cytokines interleukin-1-beta (IL-1beta) and interleukin-18 (IL-18), which may prevent or reduce inflammation. NLRP3 plays an important role in immunity and inflammation.

Dapansutrile is used as NLRP3 inflammasome inhibitors, and is used to treat multiple sclerosis.

Molecular Weight:133.17
XLogP3:-0.7
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:2
Exact Mass:133.01974964
Monoisotopic Mass:133.01974964
Topological Polar Surface Area:66.3
Heavy Atom Count:8
Complexity:190
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes